Benefit of brentuximab over bleomycin in first-line treatment of advanced-stage Hodgkin lymphoma has not been proven

Hugo J. A. Adams*, Thomas C. Kwee

*Corresponding author for this work

Research output: Contribution to journalLetterAcademicpeer-review

4 Citations (Scopus)
Original languageEnglish
Pages (from-to)339-340
Number of pages2
JournalBlood
Volume132
Issue number3
DOIs
Publication statusPublished - 19-Jul-2018

Keywords

  • END-OF-TREATMENT
  • INTERIM
  • PET
  • CHEMOTHERAPY

Cite this